A country intelligence brief on clinical trials in Lithuania; covering EU CTR alignment, cardiovascular and oncology trial potential, patient access, academic site networks, and sponsor feasibility across the Baltic research corridor.
For sponsors evaluating clinical trials in Lithuania, the country is the largest of the three Baltic states; a high-income, EU and NATO member nation of approximately 2.9 million people on the southeastern Baltic coast, bordering Latvia, Belarus, Poland, and the Kaliningrad enclave of Russia. Vilnius, the capital, is the unambiguous centre of clinical research activity, home to the country's flagship academic hospital complex and its leading oncology and neurology research institutions. Kaunas; Lithuania's second city and historical capital; is the seat of the Lithuanian University of Health Sciences (LUHS) and hosts the largest single clinical hospital complex in Lithuania. Klaipėda, Šiauliai, and Panevėžys complete the network of regional cities with established hospital infrastructure. A eurozone member since 2015, Lithuania operates with complete currency stability for European sponsors.
Clinical trials are regulated by the State Medicines Control Agency (VVKT) under the Ministry of Health, operating within the full EU Clinical Trials Regulation (CTR) framework and integrated into CTIS since implementation. Ethics review is coordinated by the Lithuanian Bioethics Committee (LBEK), which conducts Part II review in parallel with VVKT's Part I scientific assessment within EU CTR timelines. Lithuania's EU membership since 2004 means that CTIS submissions covering France, Germany, or Poland can include Lithuania at zero additional regulatory cost or complexity; a structural efficiency consistently underweighted by sponsors building EU-wide trial portfolios.
Lithuania's population is approximately 84% ethnic Lithuanian, with Polish (~6.5%), Russian (~5%), and Belarusian (~1.5%) minorities. The population is aging; an ongoing consequence of post-accession emigration to Western Europe; which paradoxically strengthens the country's clinical research proposition: the retained population skews older, carries a higher burden of non-communicable disease, and has had substantially less prior exposure to advanced pharmacotherapy than comparable Western European cohorts. Literacy stands at approximately 99.8%, and English proficiency among investigators is high, with the majority of research-active physicians having completed training exchanges at leading Western European and North American institutions. The medical community is deeply embedded in European academic networks; EORTC, ESC, ERS, and EULAR partnerships are active across major sites.
The disease burden is the defining feature of Lithuania's research profile. Cardiovascular disease accounts for approximately 55% of all deaths; one of the EU's highest rates; creating patient pools of exceptional depth for Phase III outcomes trials in heart failure, hypertension, coronary artery disease, and stroke. Cancer is the second leading cause of death, with colorectal, lung, breast, and prostate cancer driving the oncology portfolio. Type 2 diabetes prevalence is rising, and alcohol-related liver disease creates largely treatment-naïve hepatology patient pools. Mental health burden is significant, making Lithuania's psychiatric institutions genuinely valuable for CNS trial sponsors.
The cardiovascular opportunity: Lithuania's cardiovascular mortality rate is among the three highest in the European Union; a public health challenge that translates directly into a clinical research asset. Pools of patients presenting with established cardiovascular disease who have received limited or no prior advanced pharmacotherapy; particularly in heart failure, atherosclerosis, and hypertensive disease; are of a depth Western European sites have lost over decades of guideline-driven therapy rollout. For Phase III cardiovascular outcomes trials, Lithuania offers enrollment velocity structurally unavailable in Germany, France, or Spain.
Lithuania sits in a strategically distinctive position: full EU regulatory parity at Eastern European cost levels, with a high-disease-burden population and a medical community that is academically sophisticated, internationally connected, and actively seeking trial partnerships.
Full EU CTR / CTIS integration since 2004 EU accession; VVKT aligned with EMA standards; parallel LBEK ethics review within EU CTR timelines; Lithuania can be included in any EU-wide CTIS submission at zero additional regulatory cost or complexity; eurozone membership eliminates currency risk.
Per-patient and site operational costs are meaningfully below Germany, France, the Netherlands, or Scandinavia; competitive investigator fees; lower site overhead and patient management costs; a strong value-quality ratio for sponsors seeking EU-compliant data at Eastern European economics.
One of the EU's highest cardiovascular mortality rates; exceptional Phase III cardiovascular outcomes pools; large, treatment-naïve cohorts in heart failure, hypertension, and coronary disease; rising cancer and diabetes burden; high trial compliance from an educated, health-literate population.
Two established medical universities (LUHS in Kaunas, VU Faculty of Medicine in Vilnius) driving the investigator pipeline; a dedicated National Cancer Institute; major academic hospital centres in Vilnius and Kaunas; active European academic network participation; all major global CROs with Baltic operations.
Cardiovascular disease is Lithuania's dominant therapeutic area by both disease burden and trial volume; the depth of treatment-naïve patient pools in heart failure, coronary artery disease, hypertension, and stroke is unmatched by any Western European comparator at equivalent regulatory standard. Oncology is a strong second pillar, anchored by the dedicated National Cancer Institute in Vilnius and active investigator teams at both LUHS Kaunas Clinics and Santaros Klinikos; colorectal, lung, and breast cancer drive most Phase II–IV commercial activity. Neurology is a growing priority; stroke, multiple sclerosis, and neurodegenerative disease research are active at both major academic centres. Psychiatry and CNS trials benefit from Lithuania's elevated mental health burden and a large, relatively treatment-naïve patient cohort. Endocrinology, rheumatology, and respiratory disease round out a broad and increasingly commercially active portfolio.
Lithuania's clinical research activity is concentrated in Vilnius and Kaunas, which together account for the majority of Phase I–IV commercial trial volume. Regional centres in Klaipėda, Šiauliai, Panevėžys, and Alytus extend geographic reach beyond the capital-Kaunas axis.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Vilnius University Hospital Santaros Klinikos | Vilnius | Lithuania's flagship academic hospital complex and national tertiary referral centre; VU Faculty of Medicine affiliate; Phase I–IV across oncology, cardiology, neurology, haematology, endocrinology, and rheumatology; primary hub for international sponsor-led early-phase trials with active EORTC and ESC participation. |
| 02 | Hospital of Lithuanian University of Health Sciences Kaunas Clinics | Kaunas | Lithuania's largest clinical hospital complex by patient volume and main clinical base of LUHS; Phase I–IV in cardiovascular disease, oncology, neurology, pulmonology, and endocrinology; a top-enrolling site for Phase III cardiovascular outcomes trials with a deep, treatment-naïve catchment across central Lithuania. |
| 03 | National Cancer Institute (Nacionalinis vėžio institutas) | Vilnius | Lithuania's dedicated national oncology research centre; Vilnius University affiliate; Phase I–IV across solid tumours, haematologic malignancies, and radiotherapy-combined indications; active in EORTC multi-centre studies and international cooperative oncology group programmes. |
| 04 | Vilnius University Hospital Žalgiris Clinic | Vilnius | VU Faculty of Medicine affiliate specialising in orthopaedics, traumatology, rheumatology, and reconstructive surgery; Phase II–IV in inflammatory joint disease, osteoporosis, rheumatoid arthritis, and musculoskeletal indications; active EULAR network participation. |
| 05 | Republican Vilnius University Hospital | Vilnius | VU Faculty of Medicine affiliate and major multispecialty academic hospital; Phase II–IV across internal medicine, gastroenterology, dermatology, nephrology, and infectious disease; large Vilnius metropolitan catchment complementing Santaros Klinikos. |
| 06 | Klaipėda University Hospital | Klaipėda | Western Lithuania's primary academic hospital serving the Baltic port city and surrounding region; Phase II–IV in oncology, cardiovascular, respiratory, and internal medicine; collaborative research agreements with LUHS and Vilnius University. |
| 07 | Republican Hospital of Šiauliai | Šiauliai | Northern Lithuania's primary regional hospital; Phase II–IV in cardiovascular disease, oncology, and internal medicine; growing investigator training capacity supported by LUHS and VU faculty collaboration programmes. |
| 08 | Vilnius City Clinical Hospital | Vilnius | Large general hospital serving the Vilnius metropolitan population; Phase II–IV in internal medicine, cardiology, metabolic disease, and infectious disease; significant patient throughput across multiple departments. |
| 09 | Kaunas Clinical Hospital | Kaunas | Major general hospital serving Kaunas city and region, operating independently from LUHS Kaunas Clinics; Phase II–IV in cardiovascular disease, endocrinology, pulmonology, and nephrology; important second Kaunas site for multi-site enrollment. |
| 10 | Panevėžys County Hospital | Panevėžys | Central Lithuania's anchor hospital; Phase II–III in cardiovascular disease, oncology, and internal medicine; extends Lithuania's research network into a large underserved corridor between Vilnius and Šiauliai. |
| 11 | Vilnius Republican Psychiatric Hospital | Vilnius | Lithuania's primary academic psychiatric institution; Phase II–III CNS and neuropsychiatric trials across mood disorders, schizophrenia, anxiety, and neurocognitive indications; treatment-naïve cohorts attractive to international CNS sponsors. |
| 12 | Alytus County Hospital | Alytus | Southern Lithuania's primary regional hospital; Phase II–III in cardiovascular disease, oncology, and internal medicine; accesses a large rural and semi-rural patient population with limited prior trial participation. |
Lithuania's flagship academic hospital complex and national tertiary referral centre; VU Faculty of Medicine affiliate; Phase I–IV across oncology, cardiology, neurology, haematology, endocrinology, and rheumatology; primary hub for international sponsor-led early-phase trials with active EORTC and ESC participation.
Lithuania's largest clinical hospital complex by patient volume and main clinical base of LUHS; Phase I–IV in cardiovascular disease, oncology, neurology, pulmonology, and endocrinology; a top-enrolling site for Phase III cardiovascular outcomes trials with a deep, treatment-naïve catchment across central Lithuania.
Lithuania's dedicated national oncology research centre; Vilnius University affiliate; Phase I–IV across solid tumours, haematologic malignancies, and radiotherapy-combined indications; active in EORTC multi-centre studies and international cooperative oncology group programmes.
VU Faculty of Medicine affiliate specialising in orthopaedics, traumatology, rheumatology, and reconstructive surgery; Phase II–IV in inflammatory joint disease, osteoporosis, rheumatoid arthritis, and musculoskeletal indications; active EULAR network participation.
VU Faculty of Medicine affiliate and major multispecialty academic hospital; Phase II–IV across internal medicine, gastroenterology, dermatology, nephrology, and infectious disease; large Vilnius metropolitan catchment complementing Santaros Klinikos.
Western Lithuania's primary academic hospital serving the Baltic port city and surrounding region; Phase II–IV in oncology, cardiovascular, respiratory, and internal medicine; collaborative research agreements with LUHS and Vilnius University.
Northern Lithuania's primary regional hospital; Phase II–IV in cardiovascular disease, oncology, and internal medicine; growing investigator training capacity supported by LUHS and VU faculty collaboration programmes.
Large general hospital serving the Vilnius metropolitan population; Phase II–IV in internal medicine, cardiology, metabolic disease, and infectious disease; significant patient throughput across multiple departments.
Major general hospital serving Kaunas city and region, operating independently from LUHS Kaunas Clinics; Phase II–IV in cardiovascular disease, endocrinology, pulmonology, and nephrology; important second Kaunas site for multi-site enrollment.
Central Lithuania's anchor hospital; Phase II–III in cardiovascular disease, oncology, and internal medicine; extends Lithuania's research network into a large underserved corridor between Vilnius and Šiauliai.
Lithuania's primary academic psychiatric institution; Phase II–III CNS and neuropsychiatric trials across mood disorders, schizophrenia, anxiety, and neurocognitive indications; treatment-naïve cohorts attractive to international CNS sponsors.
Southern Lithuania's primary regional hospital; Phase II–III in cardiovascular disease, oncology, and internal medicine; accesses a large rural and semi-rural patient population with limited prior trial participation.
Lithuania's clinical trial ecosystem is supported by a network of regulatory bodies, academic institutions, and CROs operating across the Baltic region.
Lithuania's national competent authority for clinical trial regulation and medicinal product oversight; operates within the full EU CTR / CTIS framework; responsible for Part I scientific review of all clinical trial applications in Lithuania.
Lithuania's national ethics body responsible for Part II review of all clinical trial protocols under EU CTR; operates in parallel with VVKT within coordinated EU CTR timelines; a single national committee providing centralised ethics review.
Strategic oversight of Lithuania's healthcare system and clinical research policy; coordinates national health strategy and EU accession-driven regulatory alignment; oversees the national health insurance framework relevant to trial operations.
Lithuania's primary and largest medical university; the backbone of the national investigator pipeline affiliated with the LUHS Kaunas Clinics complex; drives GCP curriculum, international exchange, and European clinical research network participation.
Lithuania's second medical faculty and one of the oldest universities in Northern Europe; drives the investigator pipeline for Santaros Klinikos, the National Cancer Institute, Žalgiris Clinic, and all major Vilnius-based research sites.
Lithuania's dedicated national oncology research institution and an OECI-recognised cancer centre; primary engine of investigator-initiated cancer research and key partner for international commercial sponsors in Phase I–IV oncology trials.
VU's flagship biomedical and genomic research centre; drives molecular biology, cancer genomics, and pharmacogenomics research informing biomarker-driven trial designs; emerging translational science hub for precision medicine partnerships.
Global CRO with established Baltic operations covering Lithuania; Phase I–IV trial management across all major therapeutic areas; VVKT regulatory submission expertise; site monitoring, data management, and recruitment across the major Lithuanian sites.
International CRO with Baltic coverage managing Phase II–IV cardiovascular, oncology, and CNS trials in Lithuania; deep VVKT regulatory expertise and established investigator relationships across Vilnius and Kaunas.
Global CRO with Baltic operations covering Lithuania; Phase II–III trial management and EU regulatory strategy; CTIS submission expertise supporting sponsors adding Lithuanian sites to existing EU-wide trial portfolios.
CEE and Baltic-focused CRO with established Lithuanian site relationships; Phase II–IV across cardiovascular, oncology, and CNS indications; full regulatory submission, contracting, and patient recruitment management.
Lithuania is a strong but often underrecognized clinical research market within the Baltic region. It combines full EU CTR and CTIS integration, established academic hospital networks in Vilnius and Kaunas, a dedicated National Cancer Institute, and a high disease burden in cardiovascular and oncology indications. For sponsors, the country offers EU-standard trial operations, experienced investigators, competitive site economics, and access to patient populations difficult to reach in more saturated Western European markets; especially relevant for cardiovascular outcomes studies, oncology programmes, neurology, CNS research, and broader Baltic strategies where Vilnius and Kaunas can anchor multi-country feasibility across Lithuania, Latvia, and Estonia.
Keep exploring
Early-phase trials now define clinical trial design risk. See where protocol complexity, eligibility pressure, and execution challenges are forming before later phases lock them in.
AI is already influencing clinical trial design, but misconceptions delay its use until protocols are finalized, when preventable risk is already locked in.
Explore 7 key questions every trial site should ask before choosing an AI-powered clinical trial recruitment software for faster, accurate enrollment.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.